<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532776</url>
  </required_header>
  <id_info>
    <org_study_id>016-POD-001</org_study_id>
    <nct_id>NCT03532776</nct_id>
  </id_info>
  <brief_title>Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermax SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bioRASI, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dermax SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical endpoint bioequivalence (BE) study for a Podofilox Gel 0.5% formulation for the&#xD;
      treatment of external anogenital warts in comparison to Condylox® Gel 0.5% that follows the&#xD;
      study design and recommendations according to Office of Generic Drugs (OGD) of U.S. Food and&#xD;
      Drug Administration (FDA) Draft Guidance for Podofilox recommendations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, parallel group, randomized, double-blind, placebo-controlled, trial&#xD;
      with clinical endpoint comparing Podofilox Topical Gel 0.5% to Condylox® Gel 0.5% and a&#xD;
      matching placebo. The study will be conducted among adult male and female patients with&#xD;
      external anogenital warts. The Investigator will assess vital signs and perform physical&#xD;
      examination identifying any clinically significant abnormalities. Laboratory samples will be&#xD;
      collected, including HIV, Hepatitis B&amp;C, and urine pregnancy tests (UPT) for women of&#xD;
      childbearing potential. The Investigator will confirm the diagnosis of External Anogenital&#xD;
      Warts (EAW) and the absence of contraindications specified in the exclusion criterion 4&#xD;
      during the visual examination. The biopsy of skin lesions will be performed per the&#xD;
      discretion of the Investigator for microscopic verification of the diagnosis of EAWs if any&#xD;
      doubts of the diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 2, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas.</measure>
    <time_frame>28 days.</time_frame>
    <description>The primary endpoint is the Number and Percentage of subjects in the per protocol (PP) population with &quot;treatment success&quot; defined as &quot;total disappearance of all warts within all treated areas&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Application Site Reaction Scores (Erythema, Dryness, Burning/Stinging, Erosion, Edema, Pain, Itching, and Bleeding) Per Skin Reaction Scale.</measure>
    <time_frame>28 days (at visit 6)</time_frame>
    <description>Local application site reactions scores (erythema, dryness, burning/stinging, erosion, edema, pain, itching and bleeding) in each group during the study drug application period. Other adverse events including serious adverse events throughout the study participation. Local skin reaction scores for erythema, dryness, burning/stinging, erosion, edema, pain, itching and bleeding will be recorded by the Investigator for every study visit based on their intensity. Skin Reaction Scale will be used absent, mild (slight, barely perceptible), moderate (distinct presence) and severe (marked, intense).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Safety Variables Will be Based on All Adverse Events (AE).</measure>
    <time_frame>The AE reporting period for this study begins with the signature of the Informed Consent Form and, for unresolved AEs, ends 30 days following the last study medication application, a total of up to 65 days.</time_frame>
    <description>AEs will be summarized based on the frequency of AEs and their severity for all treated subjects.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">466</enrollment>
  <condition>External Anogenital Warts</condition>
  <arm_group>
    <arm_group_label>Podofilox Gel 0.5 %</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Condylox Topical Gel 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Podofilox Gel 0.5%</intervention_name>
    <description>Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
    <arm_group_label>Podofilox Gel 0.5 %</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Condylox Topical Gel 0.5%</intervention_name>
    <description>Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
    <arm_group_label>Condylox Topical Gel 0.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gel</intervention_name>
    <description>Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
    <arm_group_label>Placebo Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent prior to participating in this&#xD;
             study.&#xD;
&#xD;
          2. Male or female subjects, aged 18-65 inclusive, with a clinical diagnosis of external&#xD;
             anogenital warts (i.e., perianal warts and/or external genital warts), including two&#xD;
             or more distinct external genital warts, and wart area that is equal or less than 10&#xD;
             cm2. Histological confirmation should be obtained if there is any doubt of the&#xD;
             diagnosis.&#xD;
&#xD;
          3. Females of childbearing potential may be enrolled if they practice a method of birth&#xD;
             control with a reliability of at least 90%.&#xD;
&#xD;
          4. Sexually active study participants must agree to abstain from sexual activity of any&#xD;
             kind throughout the treatment period to prevent cross- and reinfection by HPV.&#xD;
&#xD;
          5. Any female subject with childbearing potential has a negative urine pregnancy test at&#xD;
             Baseline.&#xD;
&#xD;
          6. Negative HIV test within 4 weeks before Baseline.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          7. Female subjects who are pregnant or lactating or planning to become pregnant during&#xD;
             the study period.&#xD;
&#xD;
          8. Hypersensitivity or intolerance to Podofilox or any component of the formulation.&#xD;
&#xD;
          9. History of previous unsuccessful treatment with any formulation of Podofilox.&#xD;
&#xD;
         10. Wart area that is greater than 10 cm2.&#xD;
&#xD;
         11. Patients with internal anogenital and mucous membrane warts, Bowenoid papulosis,&#xD;
             squamous cell carcinoma, active herpes lesion, or other skin abnormalities of&#xD;
             treatment area, such as eczema, or skin that had not healed following surgery&#xD;
             (cryosurgery, laser ablation or similar).&#xD;
&#xD;
         12. Primary or secondary immunodeficiency.&#xD;
&#xD;
         13. Known presence of diabetes type I or II.&#xD;
&#xD;
         14. Local irritation in any treatment area that would interfere with treatment.&#xD;
&#xD;
         15. Use within 4 weeks prior to baseline of any: 1) treatment for anogenital warts, 2)&#xD;
             systemic corticosteroids, or 3) systemic immunosuppressive drug.&#xD;
&#xD;
         16. Any medical or surgical condition in the judgment of the Investigator that may&#xD;
             interfere with the assessment of efficacy or safety, or pose a risk to the subject.&#xD;
&#xD;
         17. Patients known to abuse alcohol and/or drugs, or with a history of chronic alcohol or&#xD;
             drug abuse that may result in protocol noncompliance.&#xD;
&#xD;
         18. Received another investigational drug, device or biologic within 90 days prior to the&#xD;
             start of Screening or has planned to participate in another clinical trial while&#xD;
             enrolled in this study.&#xD;
&#xD;
         19. Subjects who in the opinion of the investigator, are unlikely to be able to follow the&#xD;
             restrictions of the protocol and complete the study&#xD;
&#xD;
         20. Employee (or employee's family member) of the research center or private practice, CRO&#xD;
             or Sponsor, or subjects who have a conflict of interest.&#xD;
&#xD;
         21. Subjects living (e.g., siblings, spouses, relatives, roommates) in the same household&#xD;
             cannot be enrolled in the study at the same time.&#xD;
&#xD;
         22. Previous enrollment in this study, current enrollment in this study at another&#xD;
             participating site or current enrollment in another study (in parallel to this study)&#xD;
             at another clinical research site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeniy Cherepanov, MD</last_name>
    <role>Study Director</role>
    <affiliation>bioRASI, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leon Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Co, Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMC Life Research, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ecology of Health&quot; LLC</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare &quot;Chelyabinsk Regional Clinical Dermatovenerology Dispensary&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State autonoumous institution of Healthcare of Moscow region &quot;Korolev Dermatovenerology dispensary&quot;</name>
      <address>
        <city>Korolev</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Moscow scientific-practical center of Dermatovenerology and cosmetology&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Clinic of urology №1&quot; LLC</name>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State-Financed Health Institution of Healthcare &quot;Smolensk Dermatovenerologic dispensary&quot;</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare &quot;Dermatovenerologic dispensary #8&quot; of Krasnogvardeyskiy district of Saint Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Private Enterprise &quot;Dzerkalo&quot;</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal institution &quot;Ivano-Frankivsk Regional Clinical Skin and Venereal Dispensary&quot;</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;Kharkiv City Clinical Dermatovenerologic Dispensary №5&quot;</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Rivne Regional Dermatology and Venerology Dispensary&quot; of Rivne Regional Council</name>
      <address>
        <city>Rivne</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Zaporizhzhya Regional Dermatovenerology Clinical Dispensary&quot; of Zaporizhzhya Regional Council</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <results_first_submitted>April 22, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2021</results_first_posted>
  <disposition_first_submitted>October 30, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 27, 2021</disposition_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Podophyllotoxin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03532776/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03532776/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Podofilox Gel 0.5 %</title>
          <description>Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles&#xD;
Podofilox Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
        <group group_id="P2">
          <title>Condylox Topical Gel 0.5%</title>
          <description>Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles&#xD;
Condylox Topical Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
        <group group_id="P3">
          <title>Placebo Gel</title>
          <description>Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient&#xD;
Placebo Gel: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Podofilox Gel 0.5 %</title>
          <description>Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles&#xD;
Podofilox Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
        <group group_id="B2">
          <title>Condylox Topical Gel 0.5%</title>
          <description>Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles&#xD;
Condylox Topical Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
        <group group_id="B3">
          <title>Placebo Gel</title>
          <description>Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient&#xD;
Placebo Gel: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="67"/>
            <count group_id="B4" value="466"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="466"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="12.745"/>
                    <measurement group_id="B2" value="37.7" spread="11.24"/>
                    <measurement group_id="B3" value="32.3" spread="10.401"/>
                    <measurement group_id="B4" value="34.7" spread="11.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas.</title>
        <description>The primary endpoint is the Number and Percentage of subjects in the per protocol (PP) population with &quot;treatment success&quot; defined as &quot;total disappearance of all warts within all treated areas&quot;.</description>
        <time_frame>28 days.</time_frame>
        <population>Due to GCP non-compliance in site 201, two sets of Efficacy Analysis were generated: Definitive Efficacy Analysis Set excluding site 201 and Supplemental Efficacy Analysis Set including site 201. Analysis using Definitive Efficacy Analysis Set (without site 201) were considered definitive for bioequivalence. The same analyses were performed using supplemental efficacy analysis set (sensitivity analysis) and these analyses were considered supportive.</population>
        <group_list>
          <group group_id="O1">
            <title>Podofilox Gel 0.5 %</title>
            <description>Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles&#xD;
Podofilox Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Condylox Topical Gel 0.5%</title>
            <description>Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles&#xD;
Condylox Topical Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Placebo Gel</title>
            <description>Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas.</title>
          <description>The primary endpoint is the Number and Percentage of subjects in the per protocol (PP) population with &quot;treatment success&quot; defined as &quot;total disappearance of all warts within all treated areas&quot;.</description>
          <population>Due to GCP non-compliance in site 201, two sets of Efficacy Analysis were generated: Definitive Efficacy Analysis Set excluding site 201 and Supplemental Efficacy Analysis Set including site 201. Analysis using Definitive Efficacy Analysis Set (without site 201) were considered definitive for bioequivalence. The same analyses were performed using supplemental efficacy analysis set (sensitivity analysis) and these analyses were considered supportive.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE limits: -20.0% to 20.0%</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Application Site Reaction Scores (Erythema, Dryness, Burning/Stinging, Erosion, Edema, Pain, Itching, and Bleeding) Per Skin Reaction Scale.</title>
        <description>Local application site reactions scores (erythema, dryness, burning/stinging, erosion, edema, pain, itching and bleeding) in each group during the study drug application period. Other adverse events including serious adverse events throughout the study participation. Local skin reaction scores for erythema, dryness, burning/stinging, erosion, edema, pain, itching and bleeding will be recorded by the Investigator for every study visit based on their intensity. Skin Reaction Scale will be used absent, mild (slight, barely perceptible), moderate (distinct presence) and severe (marked, intense).</description>
        <time_frame>28 days (at visit 6)</time_frame>
        <population>Safety Population, 266 subjects completed the study at visit 6 (Podofilox Gel 0.5%: 114 subjects; Condylox Topical Gel 0.5%: 102 subjects and Placebo gel: 50 subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Podofilox Gel 0.5 %</title>
            <description>Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles&#xD;
Podofilox Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Condylox Topical Gel 0.5%</title>
            <description>Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles&#xD;
Condylox Topical Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Placebo Gel</title>
            <description>Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient&#xD;
Placebo Gel: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Local Application Site Reaction Scores (Erythema, Dryness, Burning/Stinging, Erosion, Edema, Pain, Itching, and Bleeding) Per Skin Reaction Scale.</title>
          <description>Local application site reactions scores (erythema, dryness, burning/stinging, erosion, edema, pain, itching and bleeding) in each group during the study drug application period. Other adverse events including serious adverse events throughout the study participation. Local skin reaction scores for erythema, dryness, burning/stinging, erosion, edema, pain, itching and bleeding will be recorded by the Investigator for every study visit based on their intensity. Skin Reaction Scale will be used absent, mild (slight, barely perceptible), moderate (distinct presence) and severe (marked, intense).</description>
          <population>Safety Population, 266 subjects completed the study at visit 6 (Podofilox Gel 0.5%: 114 subjects; Condylox Topical Gel 0.5%: 102 subjects and Placebo gel: 50 subjects).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Safety Variables Will be Based on All Adverse Events (AE).</title>
        <description>AEs will be summarized based on the frequency of AEs and their severity for all treated subjects.</description>
        <time_frame>The AE reporting period for this study begins with the signature of the Informed Consent Form and, for unresolved AEs, ends 30 days following the last study medication application, a total of up to 65 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Podofilox Gel 0.5 %</title>
            <description>Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles&#xD;
Podofilox Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Condylox Topical Gel 0.5%</title>
            <description>Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles&#xD;
Condylox Topical Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Placebo Gel</title>
            <description>Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient&#xD;
Placebo Gel: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Safety Variables Will be Based on All Adverse Events (AE).</title>
          <description>AEs will be summarized based on the frequency of AEs and their severity for all treated subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects with at least One TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One TEAE Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One Related TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One Severe TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subjects with at Least One TESAE Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AE reporting period for this study begins with the signature of the Informed Consent Form and, for unresolved AEs, ends 30 days following the last study medication application, a total of up to 65 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Podofilox Gel 0.5 %</title>
          <description>Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles&#xD;
Podofilox Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
        <group group_id="E2">
          <title>Condylox Topical Gel 0.5%</title>
          <description>Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles&#xD;
Condylox Topical Gel 0.5%: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
        <group group_id="E3">
          <title>Placebo Gel</title>
          <description>Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient&#xD;
Placebo Gel: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Application site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Application site necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any use of information, data or results related to, associated with and directly resulting from the Study shall only be published or presented only after providing a copy of the manuscript or presentation, at least 60 days in advance of such publication or presentation, to the Sponsor for its review and approval in writing. No Confidential Information may be published without the express written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chauvel Virginie</name_or_title>
      <organization>Dermax</organization>
      <phone>+32 488 07 04 18</phone>
      <email>chauvelvirginie07@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

